Yazici, A. Et Al. 2022. A national, multicenter, secondary data use study evaluating efficacy and retention of first-line biologic treatment with tocilizumab in patients with rheumatoid arthritis in real-life setting: results from TURKBIO registry.. Scientific reports , vol.12, no.1 , 21972.

Yazici, A., Özdemir Işık, Ö., Dalkılıç, E., Koca, S. S., Pehlivan, Y., Şenel, S., ... Inanc, N.(2022). A national, multicenter, secondary data use study evaluating efficacy and retention of first-line biologic treatment with tocilizumab in patients with rheumatoid arthritis in real-life setting: results from TURKBIO registry.. Scientific reports , vol.12, no.1, 21972.

Yazici, AYTEN Et Al. "A national, multicenter, secondary data use study evaluating efficacy and retention of first-line biologic treatment with tocilizumab in patients with rheumatoid arthritis in real-life setting: results from TURKBIO registry.," Scientific reports , vol.12, no.1, 21972, 2022

Yazici, AYTEN Et Al. "A national, multicenter, secondary data use study evaluating efficacy and retention of first-line biologic treatment with tocilizumab in patients with rheumatoid arthritis in real-life setting: results from TURKBIO registry.." Scientific reports , vol.12, no.1, pp.21972, 2022

Yazici, A. Et Al. (2022) . "A national, multicenter, secondary data use study evaluating efficacy and retention of first-line biologic treatment with tocilizumab in patients with rheumatoid arthritis in real-life setting: results from TURKBIO registry.." Scientific reports , vol.12, no.1, p.21972.

@article{article, author={AYTEN YAZICI Et Al. }, title={A national, multicenter, secondary data use study evaluating efficacy and retention of first-line biologic treatment with tocilizumab in patients with rheumatoid arthritis in real-life setting: results from TURKBIO registry.}, journal={Scientific reports}, year=2022, pages={21972} }